Helix Receives Milestone Payment from Lumera on Biochip License
Complete the form below to unlock access to ALL audio articles.
Helix BioPharma Corp. has announced that it has received a milestone payment of USD$125,000 from Lumera Corporation under the terms of the license agreement signed between the parties approximately one year ago.
As previously announced by Lumera, it is currently developing a high-throughput, label-free detection platform in collaboration with the Seattle-based Institute for Systems Biology ("ISB"), which may enable biologists to isolate protein samples for testing and analysis.
The initial prototype device is currently undergoing testing and further development at the ISB.
Lumera is developing specialized microarrays, combining its exclusive license to Helix's Heterodimer Protein technology (HPT) and Lumera's proprietary nanosurface modification chemistry which Lumera believes will, for the first time, allow researchers to consistently take existing DNA arrays to produce protein arrays that accurately mimic the native living cell environment of the body.
"We are extremely pleased with our relationship with Lumera," said Dr. Heman Chao, Helix' Vice President of Research.
"They are making excellent progress in the development of high density array protein chips as evidenced by their recent announcements of a collaborative agreement with Harvard Medical School (HMS) and the Harvard Institute of Proteomics, and an agreement with the Medical University of South Carolina (MUSC) to co-develop a new protein chip for the drug discovery and toxicology market."
